Inhibition of Hsp90 Alleviates Necroptosis and Inflammation in Lung Epithelial Cells During Pulmonary Ischemia–Reperfusion Injury
Clinical and Experimental Pharmacology and Physiology · 2025
DOI: 10.1111/1440-1681.70037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, 2025. Verfasst von Xiaofang Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Necroptosis, Reperfusion Injury, HSP90 Heat-Shock Proteins, Lactams, Macrocyclic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Zhejiang Provincial Natural Science Foundation of China, Zhejiang Province Traditional Chinese Medicine Science and Technology Project.
Abstract (Originalsprache)
Lung ischemia–reperfusion injury (LIRI) is a critical pathological process associated with various clinical conditions, characterised by excessive inflammatory responses and cell death, which can lead to severe respiratory dysfunction and even mortality. However, no effective therapeutic strategy is currently available. This study investigates the protective effects and underlying mechanisms of the Hsp90 inhibitor 17‐dimethylaminoethylamino (17‐DMAG) in LIRI. An in vivo mouse model of LIRI was established by transiently occluding the left pulmonary hilum with a microvascular clamp, followed by reperfusion. In vitro, necroptosis was induced in BEAS‐2B cells using TSZ (TNF‐α, Smac mimetic and z‐VAD‐FMK). Our results demonstrate that 17‐DMAG significantly attenuates lung injury, inflammation and epithelial cell necroptosis in mice. Additionally, 17‐DMAG mitigates TSZ‐induced cell death and inflammatory responses in BEAS‐2B cells. Mechanistically, 17‐DMAG inhibits the phosphorylation of RIPK1, RIPK3 and MLKL—key necroptotic regulators and client proteins of Hsp90—thereby suppressing necroptosis and reducing the associated inflammatory response. In conclusion, 17‐DMAG alleviates LIRI by inhibiting necroptosis and its consequent acute inflammatory cascade. These findings suggest that 17‐DMAG may serve as a promising therapeutic candidate for LIRI treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Lung Surgery, Zhejiang Cancer Hospital, Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Zhejiang, Hangzhou, China.
- State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China.
ORCID-Profile: Ming Wu
Förderung
- Zhejiang Provincial Natural Science Foundation of China
- Zhejiang Province Traditional Chinese Medicine Science and Technology Project
Zitieren
APA
Xu, X., Lou, Z., Li, J., Liang, F., Yu, Y., & Wu, M. (2025). Inhibition of Hsp90 Alleviates Necroptosis and Inflammation in Lung Epithelial Cells During Pulmonary Ischemia–Reperfusion Injury. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.70037
Vancouver
Xu X, Lou Z, Li J, Liang F, Yu Y, Wu M. Inhibition of Hsp90 Alleviates Necroptosis and Inflammation in Lung Epithelial Cells During Pulmonary Ischemia–Reperfusion Injury. Clinical and Experimental Pharmacology and Physiology. 2025. doi:10.1111/1440-1681.70037
BibTeX
@article{Xu2025,
author = {Xu, Xiaofang and Lou, Zhiling and Li, Jinsheng and Liang, Fuxiang and Yu, Yifan and Wu, Ming},
title = {Inhibition of Hsp90 Alleviates Necroptosis and Inflammation in Lung Epithelial Cells During Pulmonary Ischemia–Reperfusion Injury},
journal = {Clinical and Experimental Pharmacology and Physiology},
year = {2025},
doi = {10.1111/1440-1681.70037}
}
EUVIMED